InvestorsHub Logo
Followers 0
Posts 69
Boards Moderated 0
Alias Born 01/26/2006

Re: ED20332 post# 5073

Saturday, 05/12/2007 11:50:51 AM

Saturday, May 12, 2007 11:50:51 AM

Post# of 6489
Sorry ED, ALS will not generate revenue:

"Insmed is currently supplying IPLEXTM on a cost recovery basis to these Italian patients under an Expanded Access Program. Data collected through the Expanded Access Program in Italy will be used to design future ALS clinical development studies with IPLEXTM."
http://www.insmed.com/PDF/News_Press_Release42507.pdf
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent INSM News